Announcements Trials

Browse Landscape

Phase

Phase 2 20 Phase 3 4 Phase NA 2 Phase 1/2 2 Phase 4 1 Phase 2/3 1 Phase 1 1

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2 Positive Breast Cancer 1

Interventions

Cisplatin 22 pembrolizumab 17 Drug Therapy 16 Carboplatin 15 Paclitaxel 12 Gemcitabine 12 Dexamethasone 12 Magnetic Resonance Spectroscopy 10 Bevacizumab 10 venetoclax 8 atezolizumab 8 Pemetrexed 8 Oxaliplatin 8 Docetaxel 8 Specimen Handling 7 Radiotherapy 7 Nivolumab 7 Cyclophosphamide 7 Capecitabine 7 130-nm albumin-bound paclitaxel 7 Methotrexate 6 durvalumab 5 blinatumomab 5 Cytarabine 5 Androgen Antagonists 5 tislelizumab 4 spartalizumab 4 pertuzumab 4 Vincristine 4 Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Recruiting × pyrotinib × Clear all

NCT06958627 2025-05-06

any

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2/3 Recruiting

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡